TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Edwards Lifesciences (NYSE: EW) | Delayed: 89.61 +1.21 (1.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $88.40 | 52 Week High | $166.87 | |||
| Open | $88.64 | 52 Week Low | $72.20 | |||
| Day High | $89.74 | P/E | 26.05 | |||
| Day Low | $88.28 | EPS | $3.44 | |||
| Volume | 1,471,286 | |||||
